Published in Eur J Cancer on December 01, 2009
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS One (2012) 1.21
Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch (2014) 0.96
New vitamin D analogs as potential therapeutics in melanoma. Expert Rev Anticancer Ther (2012) 0.94
Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR). Am J Surg Pathol (2013) 0.91
The chick embryo as an experimental system for melanoma cell invasion. PLoS One (2013) 0.89
Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality. PLoS One (2014) 0.88
F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev (2012) 0.85
Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ (2015) 0.84
Primary retroperitoneal malignant melanoma. Pan Afr Med J (2012) 0.84
Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Ther Adv Med Oncol (2015) 0.82
Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma. BMC Cancer (2013) 0.82
Aged black garlic extract inhibits HT29 colon cancer cell growth via the PI3K/Akt signaling pathway. Biomed Rep (2014) 0.81
Marginal and joint distributions of S100, HMB-45, and Melan-A across a large series of cutaneous melanomas. Arch Pathol Lab Med (2013) 0.81
Clinical impact of (18)F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. Insights Imaging (2013) 0.81
Interferon-α abrogates tolerance induction by human tolerogenic dendritic cells. PLoS One (2011) 0.81
The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo. Mol Ther (2010) 0.79
T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma. Cancers (Basel) (2012) 0.78
Melanoma m (zero): diagnosis and therapy. ISRN Dermatol (2013) 0.78
Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells. Lasers Med Sci (2013) 0.77
Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep (2016) 0.77
Use Patterns and Costs of Isolated Limb Perfusion and Infusion in the Treatment of Regional Metastatic Melanoma: A Retrospective Database Analysis. Adv Ther (2016) 0.75
The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs. Int J Surg Case Rep (2012) 0.75
Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World J Clin Oncol (2015) 0.75
Compliance monitoring in business processes: Functionalities, application, and tool-support. Inf Syst (2015) 0.75
Limb salvage surgery following resection of a melanoma: Foot and ankle reconstruction using cutaneous flaps. Oncol Lett (2014) 0.75
Addison's disease as a presentation of metastatic malignant melanoma. Ann R Coll Surg Engl (2016) 0.75
Dinitrophenyl hapten with laser immunotherapy for advanced malignant melanoma: A clinical study. Oncol Lett (2016) 0.75
RGDechi-hCit: αvβ3 selective pro-apoptotic peptide as potential carrier for drug delivery into melanoma metastatic cells. PLoS One (2014) 0.75
Correlation of histological and ex-vivo confocal tumor thickness in malignant melanoma. Lasers Med Sci (2016) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Randomized controlled trial testing the impact of high-protection sunscreens on sun-exposure behavior. Arch Dermatol (2005) 9.42
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol (2012) 5.23
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
New common variants affecting susceptibility to basal cell carcinoma. Nat Genet (2009) 4.15
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol (2005) 2.85
The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. Ann Neurol (2015) 2.71
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res (2008) 2.56
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res (2011) 2.52
Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol (2010) 2.42
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis. J Am Acad Dermatol (2009) 2.26
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol (2013) 2.22
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Dermoscopy features of melanoma incognito: indications for biopsy. J Am Acad Dermatol (2006) 2.18
Accuracy of computer diagnosis of melanoma: a quantitative meta-analysis. Arch Dermatol (2003) 2.16
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol (2009) 2.16
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol (2005) 2.12
Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev (2003) 2.08
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
[The Nessos shirt: did Herakles die from scleroderma?]. J Dtsch Dermatol Ges (2011) 2.03
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
Identifying melanomas in primary care: can we do better? BMJ (2012) 2.01
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: systematic review. Arch Dermatol (2012) 1.97
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res (2006) 1.86
Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res (2003) 1.83
Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol (2006) 1.81
The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol (2005) 1.79
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol (2003) 1.77
An endogenous retrovirus derived from human melanoma cells. Cancer Res (2003) 1.76
Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat (2007) 1.72
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One (2011) 1.71
In vivo confocal microscopic and histopathologic correlations of dermoscopic features in 202 melanocytic lesions. Arch Dermatol (2008) 1.71
A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer (2005) 1.70
In vivo microscopic features of nodular melanomas: dermoscopy, confocal microscopy, and histopathologic correlates. Arch Dermatol (2008) 1.69
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn (2012) 1.66
Dermoscopy of pigmented lesions of the mucosa and the mucocutaneous junction: results of a multicenter study by the International Dermoscopy Society (IDS). Arch Dermatol (2011) 1.63
Dermoscopy: an aid to the detection of amelanotic cutaneous melanoma metastases. Dermatol Surg (2012) 1.59
Dermoscopic patterns of acral melanocytic nevi and melanomas in a white population in central Italy. Arch Dermatol (2006) 1.58
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. Lancet Oncol (2004) 1.57
Epidermal growth factor facilitates melanoma lymph node metastasis by influencing tumor lymphangiogenesis. J Invest Dermatol (2012) 1.57
Time required for a complete skin examination with and without dermoscopy: a prospective, randomized multicenter study. Arch Dermatol (2008) 1.53
Neurocutaneous melanosis: a fatal disease in early childhood. J Clin Oncol (2009) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol (2006) 1.52
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Association between endothelin receptor B nonsynonymous variants and melanoma risk. J Natl Cancer Inst (2005) 1.51
Dermoscopic evaluation of amelanotic and hypomelanotic melanoma. Arch Dermatol (2008) 1.51
The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). J Am Acad Dermatol (2011) 1.50
Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol (2002) 1.50
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol (2008) 1.49